- Home
- NMT vs XGN Comparison
NMT vs XGN Comparison
Compare NMT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMT | XGN |
|---|---|---|
| Founded | 1993 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 110.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMT | XGN |
|---|---|---|
| Price | $11.73 | $3.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 19.1K | ★ 710.1K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $63,599,000.00 |
| Revenue This Year | N/A | $21.40 |
| Revenue Next Year | N/A | $14.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $9.05 | $2.67 |
| 52 Week High | $10.93 | $12.23 |
Technical Indicators
Market Signals| Indicator | NMT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 18.97 |
| Support Level | $11.60 | $3.53 |
| Resistance Level | $11.72 | $4.01 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 86.94 | 4.17 |
Price Performance
Historical ComparisonAbout NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.